The critical need for colloids: Selecting the right colloid

Compendium on Continuing Education for the Practicing Veterinarian

Volumn 19, Issue 7, 1997, Pages 811-825

  Rudloff, Elke ^a,b,c   Kirby, Rebecca ^a,b,c,d  

^a Vet Inst Trauma Emergency C   (United States)

^b Animal Emergency Center   (United States)

^c Amer Coll Vet Emergency C   (United States)

^d AMER COLL OF VET INT MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000341297     PISSN: 01931903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Dextran, low molecular weight, in Sewester CS, Olin BR, Hebel SK, et al (eds): Drug Facts and Comparisons, St. Louis, Wolters Kluwer, March 1996, p 94.
2. Rainey TG, Read CA: Pharmacology of colloids and crystalloids, in Chernow B (ed): The Pharmacologic Approach to the Critically Ill Patient. Baltimore, Williams & Wilkins, 1994, pp 272-290.
3. Oz MC, Zikria BA, McLeod PF, et al: Hydroxyethyl starch macromolecules protect against increases in microvascular permeability following ischemia-reperfusion injury. Surg Forum 40:48-50, 1989.
4. Klotz U, Kroemer H: Clinical pharmacokinetic considerations in the use of plasma expanders. Clin Pharmacokinet 12:123, 1987.
5. Mishler JM: Synthetic plasma volume expanders - Their pharmacology, safety and clinical efficacy. Clin Hematol 13:75-92, 1984.
6. Thompson WL, Fukushima T, Rutherford RB, et al: Intravascular persistence, tissue storage, and excretion of hydroxyethyl starch. Surg Gynecol Obstet 131:965-972, 1970.
7. Kaminski MV, Haase TJ: Fluid resuscitation of the critically ill: Albumin and colloid osmotic pressure implications for fluid resuscitation. Crit Care Clin 8(2):311-322, 1992.
8. Tullis JL: Albumin 1: Background and use. JAMA 237: 355-359, 1977.
9. Yedger S: Tissue sites of catabolism of albumin in rats. Am J Physiol 244: E101-E107, 1983.
10. Cotter SM: Clinical transfusion medicine. Comp Trans Med 36:188-224, 1991.
11. Kirby R: Colloids: Those magic fluids. 6th IVECCS Proc. 648, 1994.
12. Doweiko JP, Nompleggi DJ: Role of albumin in human physiology and pathophysiology. J Parenter Enter Nutr 15:207-211, 1991.
13. Jusko WJ, Gretch M: Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metab Rev 5:43-140, 1976.
14. Karp WB, Kinsley M, Subramanyan SB, et al: Binding properties of glycosylated albumin and acetaldehyde albumin. Alcohol Clin Exp Res 9:429-432, 1985.
15. Lundsgaard-Hansen P, Tschirren B: Modified fluid gelatin as a plasma substitute, in Blood Substitutes and Plasma Expanders. New York, Alan R. Liss, 1978, pp 227-257.
16. Frawly JP, Artz CP, Howard JM: Plasma retention and urinary excretion of dextran and modified fluid gelatin in combat casualties. Surgery 37:784, 1955.
17. Watson J: Mechanisms of hypersensitivity to intravenous agents. Vet Res Commun 7:195-200, 1983.
18. Lutz H: Animal experiments on the effect of colloidal plasma substitutes in hemorrhagic shock in the dog. Bibl Haematol:232-247, 1969.
19. Griffel MI, Kaufman BS: Fluid resuscitation of the critically ill: Pharmacology of colloids and crystalloids. Crit Care Clin 8(2):235-253, 1992.
20. Moore RM, Bertone AL, Muir WW: Effect of high-molecular weight dextran macromolecules on low-flow ischemia and reperfusion of the large colon in horses. Am J Vet Res 57:1067-1073, 1996.
21. Huch K, Schmidt J, Schratt W, Sinn HP, et al: Hyperoncotic dextran and systemic aprotinin in necrotizing rodent pancreatitis. Scand J Gastroenterol 30:812-816, 1995.
22. Ammon R: Das Vorkommen von Dextranase im menschlichen Gewebe. Enzymologia 25:245-251, 1963.
23. Gray I: Metabolism of plasma expanders studied with carbon-14-labeled dextran. Am J Physiol 174:462-466, 1953.
24. Hauser CJ, Shoemaker WC, Turpin I: Oxygen transport responses to colloids and crystalloids in critically ill surgical patients. Surg Gynecol Obstet 150:811-816, 1980.
25. Bergqvist D: Dextrans and haemostasis: A review. Acta Chir Scand 31:320-324, 1982.
26. Aberg M, Bergentz S, Hedner U: Effect of dextran and induced thrombocytopenia on the lysability of ex vivo thrombi in dogs. Acta Chir Scand 143:91-94, 1977.
27. Aberg M, Hedner V, Bergentz S: Effect of dextran on factor VIII and platelet function. Ann Surg 189:243-247, 1979.
28. Gruber UF, Messmer K: Colloids for blood volume support. Prog Surg 15:49-76, 1977.
29. Concannon KT, Haskins SC, Feldman BF: Hemostatic defects associated with two infusion rates of dextran 70 in dogs. Am J Vet Res 53:1369-1375, 1992.
30. Rampling MW: Red cell agglutination and yield stress, in Lowe GDO (ed): Clinical Blood Rheology, Boca Raton, FL, CRC Press, 1988, pp 45-64.
31. Janes AW, Mishler JM, Lowe B: Serial infusion effects of hydroxyethyl starch on ESR, blood typing and crossmatching and serum amylase levels. Vox Sang 32:131-134, 1977.
32. Ibister JP, Fischer MD: Adverse effects of plasma volume expanders. Anaesth Intensive Care 8:145-151, 1980.
33. Matheson NA, Diomi P: Renal failure after administration of dextran 40. Surg Gynecol Obstet 131:661-668, 1970.
34. Hedin H, Richter W: Pathomechanisms of dextran-induced anaphylactoid/anaphylactic reactions in man. Int Arch Allergy Appl Immunol 68:122, 1982.
35. Dextran 1, in Sewester CS, Olin BR, Hebel SK, et al (eds): Drug Facts and Comparisons, St. Louis, Wolters Kluwer, March 1996, p 93f.
36. Webb AR, Nash GB, Dormandy JA, et al: A comparison of the effects of artificial plasma substitutes, albumin and saline solutions on in vitro apparent blood viscosity. Clin Hemorheol 10:287, 1990.
37. Webb AR, Tighe D, Moss RF, et al: Advantages of a narrow-range, medium molecular weight hydroxyethyl starch for volume maintenance in a porcine model of fecal peritonitis. Crit Care Med 19:409-416, 1991.
38. Webb AR, Barclay SA, Bennett ED: In vitro colloid osmotic pressure of commonly used plasma substitutes: A study of the diffusability of colloid molecules. Intensive Care Med 15:116, 1989.
39. Hulse JD, Yacobi A: Hetastarch: An overview of the colloid and its metabolism. Drug Intell Clin Pharm 17:334-341, 1983.
40. Khosropour R, Lackner F, Steinbereithner K, et al: Comparison of the effect of pre- and intra-operative administration of medium molecular weight hydroxyethyl starch (HES 200/0.5) and dextran 40(60) in vascular surgery. Anaesthetist 29:616, 1980.
41. Shoemaker WC, Schluchter M, Hopkins JA, et al: Fluid therapy in emergency resuscitation: Clinical evaluation of colloid and crystalloid regimens. Crit Care Med 9:367, 1981.
42. Lazrove S, Waxman K, Shippy C: Hemodynamic blood volume and oxygen transport responses to albumin and hydroxyethyl starch infusions in critically ill postoperative patients. Crit Care Med 8:302-306, 1980.
43. Rackow EC, Weil MH, MacNeil AR: Effects of crystalloid and colloid fluids on extravascular lung water in hypoproteinemic dogs. J Appl Physiol 62:2421-2425, 1987.
44. Haupt MT, Rackow EC: Colloid osmotic pressure and fluid resuscitation with hetastarch, albumin and saline solutions. Crit Care Med 10:159-162, 1982.
45. Mishler JM, Hester JP, Hustis DW, et al: Panel II: Dosage and scheduling regimens for erythrocyte-sedimenting macromolecules. J Clin Apheresis 1:130, 1983.
46. Kortilla K, Grohn P, Gordin A, et al: Effect of hydroxyethyl starch and dextran on plasma volume and blood hemostasis and coagulation. J Clin Pharmacol 24:273-282, 1984.
47. Köhler H, Zschiedrich H, Glasen R, et al: Blutvolumen, kollodosmotischer Druck und Nieren Funktion von Probanden nach Infusion mittelmolekularer 10% Hydroxyäthylstärke 200/0.5 und 10% Dextran 40. [The effects of hydroxyethyl starch 200/0.5 and 10% dextran 40 on blood volume, colloid osmotic pressure and renal function in human volunteers.] Anesthetist 31:61, 1982.
48. London M, Ho J, Triedman J, et al: A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations. J Cardiovasc Surg 97:785-797, 1989.
49. Mastroianni L, Low H, Rollman J, et al: Hemodynamic effects of pentastarch versus albumin in post open-heart surgery patients. Clin Pharmacol Ther 43:168, 1988.
50. Rackow EC, Mecher C, Asitz M, et al: Effects of pentastarch and albumin infusion on cardiorespiratory function and coagulation in patients with severe sepsis and systemic hypoperfusion. Crit Care Med 17:394-398, 1989.
51. Waxman K, Holness R, Tominga G, et al: Hemodynamic and oxygen transport effects of pentastarch in burn resuscitation. Ann Surg 209:341-345, 1988.
52. Zikria BA, Subbarao C, Oz MC, et al: Macromolecules reduce abnormal microvascular permeability in rat limb ischemia-reperfusion injury. Crit Care Med 17:1306, 1989.
53. Zimmerman BJ, Granger DN: Role of xanthine oxidase-derived oxidants and granulocytes in ischemia/reperfusion, in Schlag G, Redl H, Siegel JH (eds): Shock, Sepsis, and Organ Failure: First Wiggers Bernard Conference. New York, Springer Verlag, 1990, pp 382-403.
54. Boldt J, Mueller M, Heesen M, et al: Influence of different volume therapies and pentoxifylline infusion on circulating soluble adhesion molecules in critically ill patients. Crit Care Med 24:385-391, 1996.
55. Lewis D, Church D, Hosgood G: Effect of intravenous administration of hydroxyethyl-starch-deferoxamine on oxygen-derived free radical generation in cancellous bone specimens obtained from dogs. Am J Vet Res 11:1613-1617, 1994.
56. Hallaway PE, Eaton JW, Panter SS, et al: Modulation of deferoxamine toxicity in clearance by covalent attachment of biocompatible polymers. Proc Natl Acad Sci USA: 10108-10112, 1989.
57. Rackow EC, Falk JL, Fein A, et al: Fluid resuscitation in circulatory shock: A comparison of the cardiorespiratory effects of albumin, hetastarch and saline solutions in patients with hypovolemic and septic shock. Crit Care Med 111:839, 1983.
58. Demling RH, Harms B, Kramer G, et al: Acute versus sustained hypoproteinemia and posttraumatic pulmonary edema. Surgery 92:79, 1982.
59. Kramer GC, Harms BA, Bodai BI, et al: Effects of hypoproteinemia and increased vascular pressure on lung balance in sheep. J Appl Physiol 55:1514, 1983.
60. Harms BA, Rosenfeld DJ, Pahl AC, et al: Pulmonary transvascular fluid filtration response to hypoproteinemia and Hespan infusion. J Surg Res 48:408-414, 1990.
61. Ducey JP, Mozingo DW, Lamiell JM, et al: A comparison of the cerebral and cardiovascular effects of complete resuscitation with isotonic and hypertonic saline, hetastarch, and whole blood following hemorrhage. J Trauma 29: 1510-1518, 1989.
62. Trumble ER, Muizelaar JP, Myseros JS, et al: Coagulopathy with the use of hetastarch in the treatment of vasospasms. J Neurosurg 82:44-47, 1995.
63. Cully MD, Larson CP, Silverberg GD: Hetastarch coagulopathy in a neurosurgical patient (letter). Anesthesiology 66:706-707, 1987.
64. Damon L, Adams M, Stricker RB, Ries C: Intracranial bleed during treatment with hydroxyethyl starch (letter). N Engl J Med 317:964-965, 1987.
65. Nearman HS, Herman ML: Toxic effects of colloids in the intensive care unit. Crit Care Clin 7:713-723, 1991.
66. Ring J, Messmer K: Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1:467-469, 1977.
67. Ballinger WF II, Solanke TF, Thompson WL: Effect of hydroxyethyl starch upon survival of dogs subjected to hemorrhagic shock. Surg Gynecol Obstet 122:33, 1966.
68. Porter SS, Goldberg RJ: Intraoperative allergic reactions to hydroxyethyl starch: A report of two cases. Can Anaesthesiol Soc J 33:394-398, 1986.
69. Strauss RG: Review of the effects of hydroxyethyl starch on the blood coagulation system. Transfusion 21:299-302, 1981.
70. Macintyre E, Mackie IJ, Ho D, et al: The haemostatic effects of hydroxyethyl starch used as a volume expander. Intensive Care Med 11:300-303, 1985.
71. Howard J, Teng, C, Loeffler R: Studies of dextrans of various molecular sizes. Ann Surg 143:369-372, 1956.
72. Haass A, Stoll M, Trieb J: Hemodilution in cerebral circulatory disturbances: Indications, implementation, additional drug treatment, and alternatives, in Koscielny J, Kieswetter H, Jung F, Haass A (eds): Haemodilution: New Aspects in the Management of Circulatory Blood Flow. Improvement of Macro- and Microcirculation. New York, Springer Verlag, 1992, pp 52-114.
73. Boldt J, Knothe C, Zickmann B, et al: Influence of different intravascular volume therapies on platelet function in patients undergoing cardiopulmonary bypass. Anesth Analg 76:1185-1190, 1993.
74. Scherer R, Giebler R, Kampe S, Lox WJ: Effects of hypertonic saline hydroxyethyl starch solution on collagen-induced platelet aggregation and ATP secretion. Infusionsther Transfusionsmed 21:310-314, 1994.
75. Stump DC, Strauss RG, Henrikson RA, et al: Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII. Transfusion 25:349-354, 1985.
76. Strauss RG, Stump DC, Henrikson RA, Saunders R: Effects of hydroxyethyl starch on fibrinogen, fibrin clot formation and fibrinolysis. Transfusion 25:230-234, 1985.
77. Cheng C, Lerner MA, Lichtewnstein S, et al: Effect of hydroxyethyl starch on hemostasis. Surg Forum Metab:48-50, 1988.
78. Alexander B: Effects of plasma expanders on coagulation and hemostasis: Dextran, hydroxyethyl starch, and other macromolecules revisited. Prog Clin Biol Res 19:293-330, 1978.
79. Alexander B, Odake K, Lawlor D, et al: Coagulation, hemostasis, and plasma expanders: A quarter century enigma. Fed Proc 34:1429-1440, 1975.
80. Smiley LE, Garvey MS: The use of hetastarch as adjunct therapy in 26 dogs with hypoalbuminemia: A phase two clinical trial. J Vet Intern Med 8:195-202, 1994.
81. Karlson KE, Garzon AA, Shafton GW, Chu CJ: Increased blood loss associated with administration of certain plasma expanders: Dextran 75, dextran 40, and hydroxyethyl starch. Surgery 62:670-678, 1967.
82. Strauss RG, Stansfield RA, Henriksen RA, Villhauer PJ: Pentastarch may cause fewer side effects on coagulation than hetastarch. Transfusion 28:257-260, 1988.
83. Schildt B, Bouveng R, Sollenberg M: Plasma substitute induced impairment of the reticuloendothelial system function. Acta Chir Scand 141:7-13, 1975.
84. Shatney C, Deepika K, Militello PR, et al: Efficacy of hetastarch in the resuscitation of patients with multisystem trauma and shock. Arch Surg 118:804-809, 1983.
85. Brazeal BA, Honeycutt D, Traber LD, et al: Pentafraction for superior resuscitation of the ovine thermal burn. Crit Care Med 23:332-339, 1995.
86. Zikria BA, King TC, Stanford J, et al: A biophysical approach to capillary permeability. Surgery 105:625-631, 1989.
87. Zikria BA, Subbarao C, Goldberg G, et al: Reduction of ischemia-reperfusion injury of the myocardium by hydroxyethyl starch macromolecules. Circ Shock 78(Suppl):4, 1988.
88. Zikria BA, Subbarao C, Oz MC, et al: Hydroxyethyl starch macromolecules reduce myocardial reperfusion injury. Arch Surg 125:930-934, 1990.
89. Richter AW, Hedin HI: Dextran hypersensitivity. Immunol Today 3:132-138, 1982.